Index RUT
P/E -
EPS (ttm) -0.15
Insider Own 6.45%
Shs Outstand 62.07M
Perf Week 5.92%
Market Cap 952.16M
Forward P/E -
EPS next Y -1.65
Insider Trans -6.78%
Shs Float 58.52M
Perf Month 11.34%
Income -9.06M
PEG -
EPS next Q -0.64
Inst Own 94.83%
Short Float 14.69%
Perf Quarter -0.33%
Sales 58.75M
P/S 16.21
EPS this Y -1616.78%
Inst Trans -8.39%
Short Ratio 5.70
Perf Half Y 191.57%
Book/sh 2.46
P/B 6.19
EPS next Y 36.03%
ROA -3.04%
Short Interest 8.60M
Perf Year 123.49%
Cash/sh 3.67
P/C 4.14
EPS next 5Y -
ROE -6.15%
52W Range 4.29 - 21.88
Perf YTD 58.21%
Dividend Est. -
P/FCF -
EPS past 5Y 48.88%
ROI -4.95%
52W High -30.44%
Beta 2.18
Dividend TTM -
Quick Ratio 4.46
Sales past 5Y 15.77%
Gross Margin 69.59%
52W Low 254.78%
ATR (14) 1.10
Dividend Ex-Date -
Current Ratio 4.48
EPS Y/Y TTM 92.56%
Oper. Margin -286.38%
RSI (14) 45.48
Volatility 6.48% 7.35%
Employees 339
Debt/Eq 0.22
Sales Y/Y TTM -61.33%
Profit Margin -15.42%
Recom 1.25
Target Price 24.80
Option/Short Yes / Yes
LT Debt/Eq 0.20
EPS Q/Q -457.69%
Payout -
Rel Volume 0.38
Prev Close 15.55
Sales Surprise -67.15%
EPS Surprise -382.08%
Sales Q/Q -85.33%
Earnings Mar 07 AMC
Avg Volume 1.51M
Price 15.22
SMA20 -7.64%
SMA50 -8.29%
SMA200 52.89%
Trades
Volume 575,787
Change -2.12%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-26-24 Initiated
B. Riley Securities
Buy
$25
Apr-09-24 Upgrade
TD Cowen
Hold → Buy
Mar-04-24 Reiterated
BTIG Research
Buy
$12 → $24
Feb-14-24 Downgrade
H.C. Wainwright
Buy → Neutral
$12 → $14
Dec-20-23 Upgrade
Citigroup
Neutral → Buy
$7 → $13
Nov-07-23 Upgrade
Guggenheim
Neutral → Buy
$12
Mar-17-23 Downgrade
Guggenheim
Buy → Neutral
Nov-22-22 Downgrade
Cowen
Outperform → Market Perform
Nov-14-22 Upgrade
BMO Capital Markets
Market Perform → Outperform
$5.70 → $16
Jul-18-22 Downgrade
SMBC Nikko
Outperform → Neutral
$5
Jul-11-22 Downgrade
BMO Capital Markets
Outperform → Market Perform
$31 → $4
May-04-22 Downgrade
Guggenheim
Buy → Neutral
Feb-28-22 Upgrade
Citigroup
Neutral → Buy
$23 → $21
Feb-11-22 Initiated
BMO Capital Markets
Outperform
$31
Feb-04-22 Initiated
SMBC Nikko
Outperform
$40
Nov-17-21 Resumed
Guggenheim
Buy
$30
Oct-19-21 Initiated
JMP Securities
Mkt Outperform
$39
Oct-15-21 Resumed
BTIG Research
Buy
$50
Apr-26-21 Resumed
Credit Suisse
Outperform
$37
Mar-12-21 Upgrade
Barclays
Underweight → Overweight
$14 → $40
Show Previous Ratings
May-01-24 10:05AM
Apr-26-24 08:00AM
Apr-03-24 04:30PM
Mar-14-24 08:18AM
Mar-09-24 01:09PM
07:19AM
Loading…
Mar-08-24 07:19AM
(Thomson Reuters StreetEvents) -15.02%
12:30AM
Mar-07-24 10:42PM
09:55PM
05:30PM
04:01PM
Mar-06-24 11:29PM
Mar-01-24 05:48PM
Feb-29-24 10:00AM
Feb-27-24 05:45PM
04:30PM
Loading…
Feb-02-24 04:30PM
07:19AM
Jan-15-24 04:51PM
Jan-08-24 04:30PM
Dec-17-23 12:03PM
Nov-07-23 10:56AM
(Thomson Reuters StreetEvents) +17.10%
08:59AM
01:15AM
Nov-06-23 05:12PM
04:27PM
(Associated Press Finance)
04:01PM
Nov-02-23 04:30PM
Oct-31-23 04:30PM
Sep-05-23 07:00AM
Aug-31-23 04:30PM
07:40AM
Loading…
Aug-19-23 07:40AM
Aug-14-23 11:19AM
Aug-11-23 01:26PM
Aug-10-23 12:33PM
07:01AM
(Thomson Reuters StreetEvents)
Aug-09-23 11:30PM
05:50PM
04:52PM
04:01PM
Jul-31-23 05:35PM
Jul-05-23 11:55AM
Jun-28-23 08:12AM
Jun-08-23 07:27AM
May-14-23 08:09AM
May-10-23 12:10PM
12:30AM
May-09-23 05:25PM
04:21PM
04:01PM
May-05-23 08:27AM
May-04-23 04:30PM
Apr-25-23 10:01AM
Apr-24-23 06:15PM
Apr-07-23 08:48AM
Mar-22-23 01:22PM
Mar-20-23 06:59PM
Mar-18-23 02:52AM
Mar-17-23 06:15PM
Mar-16-23 12:17PM
07:10AM
(Thomson Reuters StreetEvents)
Mar-15-23 11:00PM
05:35PM
04:01PM
Mar-14-23 12:32PM
08:00AM
Mar-11-23 07:30AM
Mar-09-23 03:59PM
Mar-08-23 05:36PM
Mar-07-23 06:00PM
Mar-02-23 04:30PM
Feb-20-23 09:56AM
Feb-17-23 06:27AM
Feb-14-23 10:01AM
Feb-13-23 05:20PM
Feb-06-23 04:30PM
Jan-24-23 07:57AM
06:48AM
Jan-06-23 06:15PM
Jan-04-23 05:50PM
04:30PM
Jan-02-23 09:57AM
Dec-29-22 06:51AM
Dec-06-22 08:01AM
04:48AM
Dec-05-22 09:55AM
Dec-02-22 09:35AM
Nov-29-22 12:57PM
Nov-22-22 11:55AM
Nov-18-22 02:54PM
(American City Business Journals)
10:15AM
08:39AM
Nov-17-22 06:10PM
09:55AM
Nov-14-22 06:31PM
Nov-09-22 05:31AM
Nov-07-22 06:40PM
03:02PM
(American City Business Journals)
Nov-04-22 06:51PM
Nov-03-22 11:30PM
06:05PM
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Peters Jeffrey Stuart Senior VP and General Counsel Apr 04 '24 Option Exercise 4.82 42,500 204,850 51,395 Apr 08 06:07 PM Peters Jeffrey Stuart Senior VP and General Counsel Apr 04 '24 Sale 15.55 51,395 799,148 0 Apr 08 06:07 PM Peters Jeffrey Stuart Senior VP and General Counsel Mar 06 '24 Option Exercise 10.90 19,625 213,875 28,520 Mar 08 04:14 PM Peters Jeffrey Stuart Senior VP and General Counsel Mar 06 '24 Sale 21.50 19,625 421,938 8,895 Mar 08 04:14 PM Risser Eric Blasius Chief Operating Officer Mar 04 '24 Option Exercise 10.15 15,000 152,250 80,059 Mar 06 04:20 PM Spitznagel Thomas Sr VP, Technical Ops Mar 04 '24 Option Exercise 11.50 10,000 115,000 18,316 Mar 06 04:19 PM Risser Eric Blasius Chief Operating Officer Mar 04 '24 Sale 19.76 41,159 813,501 38,900 Mar 06 04:20 PM Karrels James SVP, CFO and Secretary Mar 04 '24 Sale 20.50 30,000 615,000 171,452 Mar 06 04:18 PM Spitznagel Thomas Sr VP, Technical Ops Mar 04 '24 Sale 20.00 10,000 200,000 8,316 Mar 06 04:19 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 26 '24 Sale 17.22 16,124 277,655 8,895 Feb 28 04:20 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 22 '24 Option Exercise 0.00 26,250 0 35,145 Feb 26 04:27 PM Bonvini Ezio Sr VP, Research & CSO Feb 22 '24 Option Exercise 0.00 28,125 0 110,258 Feb 26 04:26 PM Bonvini Ezio Sr VP, Research & CSO Feb 15 '24 Option Exercise 0.00 16,670 0 88,004 Feb 20 06:03 PM Risser Eric Blasius Chief Operating Officer Feb 15 '24 Option Exercise 0.00 16,670 0 70,938 Feb 20 06:04 PM Cilinski Lynn VP, Controller and Treasurer Feb 15 '24 Option Exercise 0.00 6,668 0 8,591 Feb 20 06:04 PM Koenig Scott President and CEO Feb 15 '24 Option Exercise 0.00 42,341 0 1,091,977 Feb 20 06:04 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 15 '24 Option Exercise 0.00 13,336 0 13,336 Feb 20 06:05 PM Spitznagel Thomas Sr VP, Technical Ops Feb 15 '24 Option Exercise 0.00 13,336 0 13,336 Feb 20 06:03 PM Karrels James SVP, CFO and Secretary Feb 15 '24 Option Exercise 0.00 15,003 0 206,779 Feb 20 06:04 PM Eck Stephen L. Chief Medical Officer Feb 15 '24 Option Exercise 0.00 16,670 0 16,670 Feb 20 06:41 PM Bonvini Ezio Sr VP, Research & CSO Feb 07 '24 Sale 18.00 3,334 60,012 71,334 Feb 07 04:19 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 05 '24 Option Exercise 11.11 76,251 847,355 76,251 Feb 07 04:17 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 05 '24 Sale 16.50 76,251 1,258,142 0 Feb 07 04:17 PM Bonvini Ezio Sr VP, Research & CSO Feb 01 '24 Sale 15.00 13,316 199,740 74,668 Feb 02 04:21 PM Bonvini Ezio Sr VP, Research & CSO Jan 19 '24 Sale 12.00 13,316 159,792 87,984 Jan 22 04:57 PM Bonvini Ezio Sr VP, Research & CSO Dec 20 '23 Sale 10.08 18,880 190,310 101,300 Dec 21 04:12 PM BIOTECH TARGET N V 10% Owner Oct 02 '23 Buy 4.46 150,000 669,585 9,929,963 Oct 04 03:31 PM BIOTECH TARGET N V 10% Owner Sep 07 '23 Buy 5.26 200,000 1,052,840 9,779,963 Sep 11 03:39 PM HURWITZ EDWARD Director Aug 30 '23 Buy 4.91 15,000 73,650 33,074 Sep 01 04:06 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite